arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Adagio Medical Holdings, Inc.

ADGM

$0.67 ▼ -0.04 (-4.95%) at close

14 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Adagio Medical Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $14.9M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -14.4% ↘

FCF / Share $-0.19

Trailing P/E —

Price / Book 2.6x

FCF Yield —

Debt / Equity 4.00

info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-7.00M

↑ +9.3% —

FCF / Share Free cash flow per share

$-0.19

↑ +62.1% —

Long-Term Debt Long-term obligations

$22.87M

↑ +8.7% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Debt to EquityDebt to Equity is concerning (bottom quartile)
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health

Cash Quality ↑

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2022

$0.00

FY 2023

FY 2024

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue Growth YoY (%)	—	—	N/M	—	—	—	29.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+266%)	—	—	—	—	—	—	—
EPS Growth YoY (%)	38.0% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	—	92.1% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	96.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	95.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	41.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—
Net Income Growth YoY (%)	9.3% Fair ↑ Fair Improving Year-over-year change in net income	—	-22.9% Weak ↓ Weak Declining Year-over-year change in net income	31.2% Excellent ↑ Excellent Improving Year-over-year change in net income	3.8% Caution Caution Year-over-year change in net income	—	23.5% Good Good Year-over-year change in net income	—	—	—	—	—	—	—
FCF Growth YoY (%)	62.1% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	—	53.5% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	96.7% Excellent Excellent Year-over-year change in free cash flow	94.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.59x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.40x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.35x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.18x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	—	0.84x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.24x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-14.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-9.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-19.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	—	-5.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	3.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	4.9% Caution → Caution Stable Return earned on debt + equity capital invested Optimal: > 10%	4.5% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	5.8% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—	—	—
Return on Capital (%) (%)	-13.2% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-9.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-18.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-13.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-17.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-5.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-78.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-122.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-915%)	-26.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-278%)	—	-45.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-404%)	-62.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-515%)	—	-10.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-172%)	4.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-73%)	5.7% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-62%)	6.5% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-56%)	8.7% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-42%)	—	—	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Debt to Equity (x)	4.00x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+566%)	1.70x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+183%)	-16.15x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-2792%)	1.96x Weak ↑ Weak Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+226%)	1.42x Caution ↑ Caution Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+137%)	-0.12x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-119%)	0.18x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-70%)	—	—	-0.29x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-148%)	—	—	—	—
Interest Coverage (x)	—	—	—	—	—	—	—	-201.79x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-205.00x Weak Weak Operating income divided by interest expense Optimal: > 5x	-98.76x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$9.96M	$3.94M	$16.52M	$8.74M	$4.69M	$-3.41M	$-14.51M	—	—	$36.88M	—	—	—	—
Debt / EBITDA (x)	-4.58x Excellent → Excellent Stable Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-5.64x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-3.83x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-3.81x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-2.48x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	-2.33x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	-7.36x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 8 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	$0.00	—	$0.00	—	—	—	$0.00	$0.33	$0.03	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.31	$-0.09	$-0.66	$-0.26	$-0.50	—	$-8.34	$-7.35	$-10.28	$-11.33	$-14.15	—	—	—
Free Cash Flow per Share (USD)	$-0.19	—	$-0.23	$-0.30	$-0.49	—	$-0.49	$-9.13	$-8.85	—	—	—	—	—
Dividend per Share (USD)	—	—	—	—	—	—	—	—	—	$0.00	—	$0.00	$0.00	—
Book Value per Share (USD)	$0.26	$0.56	$-0.09	$0.56	$0.81	$-190.17	$5.27	$-180.16	$-181.41	$-169.28	—	—	—	—
Tangible Book Value per Share (USD)	$-0.68	$-0.38	$-1.45	$-0.80	$-0.56	$-217.01	$0.43	$-180.16	$-181.41	$-169.28	—	—	—	—
Basic Weighted Avg Shares (shares)	22.21M	—	15.38M	15.38M	15.38M	—	14.06M	779,908	779,908	—	—	—	—	—
Dividend Payout Ratio (%)	—	—	—	—	—	—	—	—	—	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$7.28M	$11.85M	$-1.56M	$7.34M	$11.37M	$17.59M	$27.11M	—	—	$-41.99M	—	—	—	—
LT Debt (USD)	$22.87M	$21.04M	$21.19M	$16.95M	$17.65M	$17.18M	$13.75M	—	—	$38.27M	—	—	—	—
Total Equity (USD)	$5.72M	$12.40M	$-1.31M	$8.67M	$12.40M	$-148.31M	$76.56M	$-140.51M	$-141.48M	$-132.02M	$-123.51M	—	—	$-95.88M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Dec 31, 2023 10-Q ↗	Q1 FY2023 Dec 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$0.00	—	—	—	$53.00K	$254.00K	$26.00K	$78.00K	$41.00K	—	—	—
Depreciation Expense (USD)	$210.00K	$237.00K	$191.00K	$271.00K	$271.00K	—	$316.00K	$257.00K	$330.00K	$133.00K	$100.00K	—	—	—
Net Income, GAAP (USD)	$-7.00M	$-3.31M	$-10.12M	$-3.95M	$-7.71M	—	$-8.23M	$-5.73M	$-8.02M	$-8.62M	$-10.76M	—	—	—
Operating Cash Flow (USD)	$-4.13M	$-4.14M	$-3.01M	$-4.66M	$-7.21M	—	$-6.36M	$-6.95M	$-6.74M	$-7.09M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

Adagio Medical Holdings, Inc.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ADGM with peers